Diclofenac Infusion Protocol for Temperature Control in Febrile Patients

Direct Recommendation

For febrile critically ill patients requiring temperature control therapy, administer diclofenac sodium as a continuous intravenous infusion at 0.04 mg/kg/h for up to 48 hours, rather than as bolus injections, to achieve sustained normothermia (temperature <37.5°C) while minimizing adverse cerebral effects.

Dosing Protocol

Standard Continuous Infusion Regimen

Dose: 0.04 mg/kg/h as continuous IV infusion 1
Duration: Up to 48 hours for sustained fever control 1
Target: Core temperature <37.5°C 1

Alternative Bolus Dosing (Less Preferred)

Initial dose: 0.2 mg/kg IV bolus 2
Duration of effect: Approximately 6 hours 2
Limitation: Requires repeated dosing and may cause greater hemodynamic fluctuations

Critical distinction: Extended infusions (12 hours) are associated with small but significant decreases in brain tissue oxygen (PtO2 from 23.1 to 21.7 mmHg) even when cerebral perfusion pressure is maintained 3. However, continuous low-dose infusions (0.04 mg/kg/h) actually improve intracranial pressure and cerebral perfusion pressure while achieving normothermia 1.

Dilution and Administration

Preparation

Dilute diclofenac sodium in compatible IV solution (normal saline or dextrose)
Calculate total dose based on patient weight and infusion duration
Use infusion pump for precise delivery

Infusion Rate

For 70 kg patient: approximately 2.8 mg/h (0.04 mg/kg/h × 70 kg)
Adjust proportionally for actual body weight
Maintain constant rate throughout infusion period

Monitoring Parameters

Mandatory Monitoring

Temperature Monitoring 4

Use central temperature methods when available: pulmonary artery thermistor, bladder catheter, or esophageal thermistor
If central monitoring unavailable, use oral or rectal temperatures
Avoid axillary, tympanic, or temporal artery methods (unreliable)
Monitor every 4 hours minimum 1

Cerebral Parameters (if monitoring in place) 1, 3

Intracranial pressure (ICP): Expect reduction with low-dose continuous infusion
Cerebral perfusion pressure (CPP): Should improve or remain stable
Brain tissue oxygen (PtO2): Monitor for decreases, particularly with extended infusions
Check every 4 hours during infusion

Hemodynamic Parameters 1, 2

Mean arterial pressure (MAP): Should remain stable
Heart rate: Expect modest decrease (84 to 77 bpm) 3
Monitor every 4 hours

Renal Function 1, 2

Baseline and 48-hour creatinine, BUN
Urinary output: Maintain >0.5 mL/kg/h
Transient changes may occur but typically do not require intervention 2

Hepatic Function 1

Baseline and 48-hour transaminases
Monitor for hepatotoxicity, though rare at these doses

Contraindications and Precautions

Absolute Contraindications

Renal failure (specifically excluded from safety studies) 2
Hypovolemia (specifically excluded from safety studies) 2
Active gastrointestinal bleeding
Known hypersensitivity to NSAIDs

Relative Contraindications

Coagulopathy or anticoagulation therapy
Recent neurosurgical intervention (assess bleeding risk)
Severe hepatic impairment
Cardiovascular instability requiring high-dose vasopressors

Special Populations

Septic Shock Patients 5

Guidelines suggest targeting normothermia in septic shock 5
NSAIDs showed no mortality benefit but effectively controlled temperature 5
Caution: Fever may have protective role in bacterial infections; consider allowing permissive fever (38-38.4°C) in septic patients 5

Bacterial Meningitis 5

Without intracranial hypertension: Target normothermia 5
With intracranial hypertension: Consider targeted temperature management 34-36°C 5
Fever inhibits replication of N. meningitidis and S. pneumoniae 5

Clinical Context and Guideline Framework

When to Use Antipyretics

The 2023 Critical Care Medicine guidelines recommend AGAINST routine antipyretic use solely for temperature reduction in critically ill febrile patients 4. However, antipyretics are suggested when:

Patient values comfort through temperature reduction 4
Specific neurological conditions require strict temperature control
Intracranial hypertension is present

Preferred Method for Temperature Control

When temperature control is indicated, use servo-regulated cooling devices rather than pharmacologic agents alone 5. Diclofenac should be considered adjunctive therapy or when advanced cooling methods are unavailable.

Practical Algorithm

Assess indication: Is temperature control truly necessary, or is fever physiologically beneficial?
Exclude contraindications: Verify no renal failure, hypovolemia, or active bleeding
Establish monitoring: Central temperature monitoring + hemodynamic monitoring
Initiate infusion: 0.04 mg/kg/h continuous IV infusion
Monitor response: Temperature every 4 hours; expect normothermia within 3 hours 1
Assess cerebral effects: If ICP/PtO2 monitoring present, verify improvement or stability
Continue up to 48 hours: Reassess need for ongoing therapy daily
Monitor for complications: Renal function, hepatic function, bleeding

Common Pitfalls

Using bolus dosing instead of continuous infusion: Bolus administration causes greater hemodynamic fluctuations and requires repeated dosing
Ignoring renal function: Diclofenac is contraindicated in renal failure; this is not a relative contraindication
Aggressive temperature reduction in sepsis: Permissive fever may be beneficial in bacterial infections 5
Using unreliable temperature monitoring: Axillary and tympanic measurements are inadequate for critically ill patients 4
Assuming all fever requires treatment: Guidelines recommend against routine antipyretic use 4

What is the recommended diclofenac sodium infusion protocol (dose, dilution, infusion rate, frequency, monitoring parameters, and contraindications) for a febrile patient undergoing temperature‑control therapy?

Have a follow-up question?